HIPGEN is a multi-center clinical phase III trial led by Charité - Universitätsmedizin Berlin, sponsored by Pluristem Inc (NASDAQ: PSTI) and funded by the Horizon 2020 program of the European Commission. The project aims at bringing the first regenerative therapy for improving recovery following a surgically treated injury to market approval. The major focus of HIPGEN is patients who are undergoing total or hemi- arthoplasty.
Be the Partner has joined leading provider of technology-enabled clinical trial solutions Bioclinica’s eHealth App xChange. The partnership provides clinical researchers and sponsors expanded choices in patient-centric applications they can leverage as part of Bioclinica’s extensive and growing eHealth platform.